Personalised Nanomedicine for Cancer Management - Olerile, Livesey D.
16,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Paclitaxel, a drug of choice for treatment of sundry human cancers, has been used for several decades. Successful paclitaxel treatment relies on the stage of cancer the patient is at. Biological aptitudes considered to be cancer hallmarks are: proliferative signaling, evasion of growth suppressors, resistance to cell death, explicative immortality, angiogenesis, invasion and metastasis. With these numerous steps involved in cancer progression, the patient survival prospect is dependent on the ability to respond timely to changes in treatment protocol. A theragnostic system certainly confers…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Paclitaxel, a drug of choice for treatment of sundry human cancers, has been used for several decades. Successful paclitaxel treatment relies on the stage of cancer the patient is at. Biological aptitudes considered to be cancer hallmarks are: proliferative signaling, evasion of growth suppressors, resistance to cell death, explicative immortality, angiogenesis, invasion and metastasis. With these numerous steps involved in cancer progression, the patient survival prospect is dependent on the ability to respond timely to changes in treatment protocol. A theragnostic system certainly confers that scaffold. The system bestows new methodologies to monitor, evaluate and individualise treatment in real-time. Imaging agent, quantum dots are known to possess unique properties that make them ideal for imaging purpose. Nanostructured lipid carriers present opportunity to offer single unit platform for designing a multifunctional nanoparticle with potential to merging imaging and therapeutic functions.
Autorenporträt
Dr. Livesey D. Olerile is a seasoned Scientist, a reviewer for Elsevier journal and Co-patent holder (Developing Oxytocin Dry Powder Inhaler for postpartum haemorrhage prevention and treatment in developing world, which completed Phase 1 of clinical trials under the auspices of the British Pharmaceutical giant, GlaxoSmithKline).